These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21525185)

  • 21. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.
    Wennerberg E; Pfefferle A; Ekblad L; Yoshimoto Y; Kremer V; Kaminskyy VO; Juhlin CC; Höög A; Bodin I; Svjatoha V; Larsson C; Zedenius J; Wennerberg J; Lundqvist A
    Clin Cancer Res; 2014 Nov; 20(22):5733-44. PubMed ID: 25212604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
    Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
    J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen.
    Kellner C; Lutz S; Oberg HH; Wesch D; Otte A; Diemer KJ; Wilcken H; Bauerschlag D; Glüer CC; Wichmann C; Kabelitz D; Leusen JHW; Klausz K; Humpe A; Gramatzki M; Peipp M
    Biol Chem; 2022 Apr; 403(5-6):545-556. PubMed ID: 34717050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Fusion Antibody Exhibits Antiangiogenic Activity and Stimulates NK Cell-mediated Immune Surveillance Through Fused NKG2D Ligand.
    Acheampong DO; Tang M; Wang Y; Zhao X; Xie W; Chen Z; Tian W; Wang M; Zhang J
    J Immunother; 2017 Apr; 40(3):94-103. PubMed ID: 28234666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
    Mei JZ; Guo KY; Wei HM; Song CY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells.
    Guo C; Wang X; Zhang H; Zhi L; Lv T; Li M; Lu C; Zhu W
    Mol Immunol; 2019 Oct; 114():108-113. PubMed ID: 31351411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.
    Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R
    Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein.
    Zou Y; Luo W; Guo J; Luo Q; Deng M; Lu Z; Fang Y; Zhang CC
    Eur J Immunol; 2018 Oct; 48(10):1750-1763. PubMed ID: 30063799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
    Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
    J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutting edge: NKG2D-dependent cytotoxicity is controlled by ligand distribution in the target cell membrane.
    Martinez E; Brzostowski JA; Long EO; Gross CC
    J Immunol; 2011 May; 186(10):5538-42. PubMed ID: 21464092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
    Wittenbrink M; Spreu J; Steinle A
    Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural killer cell-mediated shedding of ULBP2.
    Wang R; Sun PD
    PLoS One; 2014; 9(3):e91133. PubMed ID: 24614922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of the NKG2D Ligand ULBP2 by JC Polyomavirus Infection Promotes Immune Recognition by Natural Killer Cells.
    Jost S; Ahn J; Chen S; Yoder T; Gikundiro KE; Lee E; Gressens SB; Kroll K; Craemer M; Kaynor GC; Lifton M; Tan CS
    J Infect Dis; 2024 Jun; 229(6):1836-1844. PubMed ID: 37774496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
    Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
    Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
    Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
    J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation.
    Hood SP; Foulds GA; Imrie H; Reeder S; McArdle SEB; Khan M; Pockley AG
    Front Immunol; 2018; 9():3169. PubMed ID: 30761160
    [No Abstract]   [Full Text] [Related]  

  • 39. MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation.
    Tietje A; Li J; Yu X; Wei Y
    Gene Ther; 2014 May; 21(5):468-75. PubMed ID: 24572784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.
    Wu JD; Higgins LM; Steinle A; Cosman D; Haugk K; Plymate SR
    J Clin Invest; 2004 Aug; 114(4):560-8. PubMed ID: 15314693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.